Enhanc3D Genomics

Enhanc3D Genomics develops functional genomics platforms that map the human three dimensional genome to transform therapeutic development.

Cambridge, UK—Website

£10.0MTotal raised

Enhanc3D Genomics is a functional genomics company that unlocks the potential of the human three-dimensional genome to transform therapeutic development. Its proprietary platform maps DNA interactions to identify novel disease biomarkers and treatment targets.

Team

Chris Torrance

Non-Executive Chair

Peter Fraser

Professor

Peter brings academic and research experience from Florida State University, Peking Union Medical College, and The Babraham Institute. He also founded Enhanc3D Genomics.

Debora Lucarelli

Chief Executive Officer

Debora brings technical and executive experience from roles at Tagomics, Enhanc3D Genomics, and Cambridge Epigenetix. She previously held research positions at Oxford Nanopore Technologies and the University of Cambridge.

Frank Armstrong

Frank brings extensive life sciences board and chair experience, alongside advisory work for private equity and venture capital investors. He currently serves as chair at Biocaptiva and Enhanc3D Genomics, following previous chair roles at Newcells Biotech, Caldan Therapeutics, and Faron Pharmaceuticals.

Jonathan Milner

Private Investor